Pharma BD Deal Intelligence
Amgen Inc. / Otezla (from Celgene/BMS)
2019 · Asset Purchase · $13.4B · Complete
Announcement Sentiment
58
Neutral / mixed
Outcome Score
68
Largely worked — most objectives met.
Amgen acquired Otezla (apremilast) for $13.4B from Celgene psoriasis drug divestiture.
Key facts
- Announced Aug 26, 2019
- Closed Nov 21, 2019
- Deal value $13.4B
- Deal type Asset Purchase
- Therapeutic area Dermatology, Immunology
- Key assets Otezla
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals